Diligence memo · auto-generated · as of July 2, 2026
Primus Therapeutics Inc.
Primus Therapeutics Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Primus Therapeutics Inc. operates in Pharmaceuticals, based in SKILLMAN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Primus Therapeutics Inc. has raised $800K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $500K on 2010-07-12.
Most recent recorded round closed around 2011-01-25.
Valuation (modeled)modeled
Provath models Primus Therapeutics Inc. at approximately $14M (range $168K–$161M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.75× the median modeled value of Pre-Seed Pharmaceuticals companies in 2010–2012 (71 peers) — value vs value, same stage and era. Within the normal band (75% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 15.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 17% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Dermal Life, LLC, Armgo Pharma Inc, Third Day Healing Holdings LLC, Dermamedics Llc, China Yongxin Pharmaceuticals Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.